Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Receives Consensus Recommendation of “Buy” from Brokerages

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has earned an average recommendation of “Buy” from the seven analysts that are currently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among brokerages that have updated their coverage on the stock in the last year is $14.3333.

Several research analysts have recently commented on the company. Leede Financial upgraded Eupraxia Pharmaceuticals to a “strong-buy” rating in a research report on Wednesday, October 29th. Cantor Fitzgerald lifted their price objective on shares of Eupraxia Pharmaceuticals from $11.00 to $19.00 and gave the stock an “overweight” rating in a report on Thursday, January 15th. Lifesci Capital raised shares of Eupraxia Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 11th. Wall Street Zen upgraded shares of Eupraxia Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Saturday, December 13th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Eupraxia Pharmaceuticals in a report on Friday, January 9th.

Eupraxia Pharmaceuticals Stock Performance

NASDAQ:EPRX opened at $8.42 on Monday. The company has a market capitalization of $302.78 million, a price-to-earnings ratio of -9.68 and a beta of 1.20. Eupraxia Pharmaceuticals has a one year low of $2.68 and a one year high of $9.32. The stock has a 50-day simple moving average of $7.81 and a 200 day simple moving average of $6.45.

Institutional Trading of Eupraxia Pharmaceuticals

Several hedge funds have recently made changes to their positions in EPRX. Quadrature Capital Ltd acquired a new position in Eupraxia Pharmaceuticals during the 2nd quarter valued at approximately $61,000. TCI Wealth Advisors Inc. bought a new stake in Eupraxia Pharmaceuticals in the third quarter valued at $65,000. Integrated Wealth Concepts LLC acquired a new position in shares of Eupraxia Pharmaceuticals during the third quarter valued at $71,000. Bank of America Corp DE grew its position in shares of Eupraxia Pharmaceuticals by 402.4% during the second quarter. Bank of America Corp DE now owns 12,559 shares of the company’s stock worth $72,000 after acquiring an additional 10,059 shares during the last quarter. Finally, Geode Capital Management LLC acquired a new stake in shares of Eupraxia Pharmaceuticals in the 4th quarter worth about $105,000.

About Eupraxia Pharmaceuticals

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.